Efficacy of Initial Treatment with Clevudine in Naive Patients with Chronic Hepatitis B
![]() |
Yang, Hyeon-Woong
(Department of Internal Medicine, Eulji University School of Medicine)
Lee, Byung-Seok (Department of Internal Medicine, Chungnam National University School of Medicine) Lee, Tae-Hee (Department of Internal Medicine, Konyang University College of Medicine) Lee, Heon-Young (Department of Internal Medicine, Chungnam National University School of Medicine) Nam, Kwan-Woo (Department of Internal Medicine, Chungnam National University School of Medicine) Kang, Young-Woo (Department of Internal Medicine, Konyang University College of Medicine) Chae, Hee-Bok (Department of Internal Medicine, Chungbuk National University College of Medicine) Kim, Seok-Hyun (Department of Internal Medicine, Chungnam National University School of Medicine) Kim, Seok-Bae (Department of Internal Medicine, Dankook University College of Medicine) Lee, Hyang-Ie (Department of Internal Medicine, Eulji University School of Medicine) Kim, An-Na (Department of Internal Medicine, Eulji University School of Medicine) Song, Il-Han (Department of Internal Medicine, Dankook University College of Medicine) Lee, Sae-Hwan (Department of Internal Medicine, Soonchunhyang University College of Medicine) Kim, Hong-Su (Department of Internal Medicine, Soonchunhyang University College of Medicine) |
1 | Yoo BC, Kim JH, Chung YH, et al. Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology 2007;45:1172-1178. DOI ScienceOn |
2 | Lim SG, Leung N, Hann HW, et al. Clinical trial: a phase II, randomized study evaluating the safety, pharmacokinetics and anti-viral activity of clevudine for 12 weeks in patients with chronic hepatitis B. Aliment Pharmacol Ther 2008;27:1282-1292. DOI ScienceOn |
3 | Niu C, Murakami E, Furman PA. Clevudine is efficiently phosphorylated to the active triphosphate form in primary human hepatocytes. Antivir Ther 2008;13:263-269. |
4 | Kim MH, Kim KA, Lee JS, et al. Efficacy of 48-week clevudine therapy for chronic hepatitis B. Korean J Hepatol 2009;15:331-337. DOI ScienceOn |
5 | Fischer KP, Gutfreund KS, Tyrrell DL. Lamivudine resistance in hepatitis B: mechanisms and clinical implications. Drug Resist Updat 2001;4:118-128. DOI ScienceOn |
6 | Ferenci P. Treatment of chronic viral hepatitis. Best Pract Res Clin Gastroenterol 2004;18 Suppl:113-120. DOI ScienceOn |
7 | Locarnini S. Molecular virology and the development of resistant mutants: implications for therapy. Semin Liver Dis 2005;25 Suppl 1:9-19. DOI |
8 | Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003;125:1714-1722. DOI ScienceOn |
9 | Matthews SJ. Entecavir for the treatment of chronic hepatitis B virus infection. Clin Ther 2006;28:184-203. DOI ScienceOn |
10 | Koh KH, Kang CJ, Kim DH, et al. Development of clevudine resistance after switching from lamivudine in a patient with chronic hepatitis B. Korean J Gastroenterol 2008;52:325-328. |
11 | Liu SH, Grove KL, Cheng YC. Unique metabolism of a novel antiviral L-nucleoside analog, 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil: a substrate for both thymidine kinase and deoxycytidine kinase. Antimicrob Agents Chemother 1998;42:833-839. |
12 | Marcellin P, Mommeja-Marin H, Sacks SL, et al. A phase II doseescalating trial of clevudine in patients with chronic hepatitis B. Hepatology 2004;40:140-148. |
13 | Lee HS, Chung YH, Lee K, et al. A 12-week clevudine therapy showed potent and durable antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology 2006;43:982-988. DOI ScienceOn |
14 | Yoo BC, Kim JH, Kim TH, et al. Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression. Hepatology 2007;46:1041-1048. DOI ScienceOn |
15 | Lee KS, Byun KS, Chung YH, et al. Clevudine therapy for 24 weeks further reduced serum hepatitis B virus DNA levels and increased ALT normalization rates without emergence of viral breakthrough than 12 weeks of clevudine therapy. Intervirology 2007;50:296-302. DOI ScienceOn |
![]() |